IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6

Institute of Biochemistry, Christian-Albrechts-University of Kiel, Kiel, Germany.
International journal of biological sciences (Impact Factor: 4.51). 10/2012; 8(9):1237-47. DOI: 10.7150/ijbs.4989
Source: PubMed


Interleukin-6 (IL-6) is a cytokine with many activities. It has functions in the regulation of the immune system and the nervous system. Furthermore, IL-6 is involved in liver regeneration and in the metabolic control of the body. On target cells, IL-6 binds to an 80 kDa IL-6 receptor (IL-6R). The complex of IL-6 and IL-6R associates with a second protein, gp130, which thereupon dimerizes and initiates intracellular signaling. Whereas gp130 is expressed on all cells, IL-6R is only present on few cells in the body including hepatocytes and some leukocytes. Cells, which do not express IL-6R cannot respond to the cytokine, since gp130 alone has no measurable affinity for IL-6. Interestingly, a soluble form of IL-6R (sIL-6R) comprising the extracellular portion of the receptor can bind IL-6 with a similar affinity as the membrane bound IL-6R. The complex of IL-6 and sIL-6R can bind to gp130 on cells, which do not express the IL-6R, and which are unresponsive to IL-6. This process has been called trans-signaling. Here I will review published evidence that IL-6 trans-signaling is pro-inflammatory whereas classic IL-6 signaling via the membrane bound IL-6R is needed for regenerative or anti-inflammatory activities of the cytokine. Furthermore, the detailed knowledge of IL-6 biology has important consequences for therapeutic strategies aimed at the blockade of the cytokine IL-6.

Download full-text


Available from: Stefan Rose-John,
  • Source
    • "Bearing this in mind, a likely explanation for this result is that the suppression of the first line of defences by androgens could increase susceptibility to pathogens or parasites, leading to a subsequent activation of these immunological variables . Il-6 is a protein required for the activation of the immune system (Rose-John, 2012) and is considered a main inflammatory marker (Kishimoto, 2005; Raman et al., 2013). It is assumed that mounting an immune response has energetic and/or nutrient costs which may interfere with metabolic processes (Demas et al., 1997), resulting in a possible loss of body weight. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Female birds may adjust their offspring phenotype to the specific requirements of the environment by differential allocation of physiologically active substances into yolks, such as androgens. Yolk androgens have been shown to boost embryonic development, growth rate and competitive ability of nestlings, but they can also entail immunological costs. The balance between costs and benefits of androgen allocation is expected to depend on nestling environment. We tested this hypothesis in a multi-brooded passerine, the spotless starling, Sturnus unicolor. We experimentally manipulated yolk androgen levels using a between-brood design, and evaluated its effects on nestling development, survival and immune function. Both in first and replacement broods, the embryonic development period was shorter for androgen-treated chicks than controls, but there were no differences in second broods. In replacement broods, androgen-treated chicks were heavier and larger than those hatched from control eggs, but this effect was not observed in the other breeding attempts. Androgen exposure reduced survival with respect to controls only in second broods. Regarding immune function, we detected non-significant trends for androgen treatment to activate two important components of innate and adaptive immunity (IL-6 and Ig-A levels, respectively). Similarly, androgen-treated chicks showed greater lymphocyte proliferation than controls in the first brood and an opposite trend in the second brood. Our results indicate that yolk androgen effects on nestling development and immunity depend on the environmental conditions of each breeding attempt. Variation in maternal androgen allocation to eggs could be explained as the result of context-dependent optimal strategies to maximize offspring fitness. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Journal of Evolutionary Biology 06/2015; 28(8). DOI:10.1111/jeb.12668 · 3.23 Impact Factor
  • Source
    • "However, during inflammatory conditions, IL-6 levels can increase up to a millionfold [10], whereas serum concentrations of sIL-6R and sgp130 show much smaller differences between healthy and diseased and in most cases do not rise by more than a factor of 2 [15]. These concentrations imply that IL-6, once secreted, will bind to sIL-6R in the serum and this complex will associate with sgp130, and thereby be neutralized [8]. Only when IL-6 levels exceed the levels of sIL-6R and sgp130, IL-6 can act systematically-as seen under septic conditions [10]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In 1998, a systemic fetal cytokine response, defined as a plasma interleukin-6 (IL-6) value above 11pg/mL, was reported to be a major independent risk factor for the subsequent development of neonatal morbid events even after adjustments for gestational age and other confounders. Since then, the body of literature investigating the use of blood concentrations of IL-6 as a hallmark of the fetal inflammatory response syndrome (FIRS), a diagnostic marker of early-onset neonatal sepsis (EONS) and a risk predictor of white matter injury (WMI), has grown rapidly. In this article, we critically review: IL-6 biological functions; current evidence on the association between IL-6, preterm birth, FIRS and EONS; IL-6 reference intervals and dynamics in the early neonatal period; IL-6 response during the immediate postnatal period and perinatal confounders; accuracy and completeness of IL-6 diagnostic studies for EONS (according to the Standards for Reporting of Diagnostic Accuracy statement); and recent breakthroughs in the association between fetal blood IL-6, EONS, and WMI. Copyright © 2015 Elsevier Ltd. All rights reserved.
    Cytokine 04/2015; 76(1). DOI:10.1016/j.cyto.2015.03.015 · 2.66 Impact Factor
  • Source
    • "IL-6 exerts its activity through interaction with a receptor complex composed of the nonsignaling alpha subunit IL-6R (CD126) and the common, ubiquitously expressed, beta subunit gp130 (CD130), resulting in immediate activation of receptor-associated kinases (JAK1/JAK2 and TYK2) and subsequent regulation of STAT1/STAT3 and SHP2-MAPK signaling pathways (Figure 1) [68, 70, 71]. The IL-6R subunit functions in vivo as both a conventional membrane-bound receptor, expressed on the surface of hepatocytes and certain inflammatory cells, and a soluble form (sIL-6R) which forms active IL-6/sIL-6R complexes (IL-6 transsignaling) [72, 73]; this property is unique to IL-6 among currently known cytokines [68–70]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Psoriasis vulgaris (PV) is a cutaneous inflammatory disorder stemming from abnormal, persistent activation of the interleukin- (IL-)23/Th17 axis. Pustular psoriasis (PP) is a clinicopathological variant of psoriasis, histopathologically defined by the predominance of intraepidermal collections of neutrophils. Although PP pathogenesis is thought to largely follow that of (PV), recent evidences point to a more central role for IL-1, IL-36, and IL-6 in the development of PP. We review the role of IL-6 in the pathogenesis of PV and PP, focusing on its cross-talk with cytokines of the IL-23/Th17 axis. Clinical inhibitors of IL-6 signaling, including tocilizumab, have shown significant effectiveness in the treatment of several inflammatory rheumatic diseases, including rheumatoid arthritis and juvenile idiopathic arthritis; accordingly, anti-IL-6 agents may potentially represent future promising therapies for the treatment of PP.
    Research Journal of Immunology 07/2014; 2014(85):964069. DOI:10.1155/2014/964069
Show more